Overview
Acute schistosomiasis, also known as acute schistosomiasis or Katayama fever, primarily affects non-immune individuals, particularly travelers and residents in low-endemic areas, leading to severe systemic reactions within weeks of initial cercariae exposure 2. Clinically, it manifests with fever, eosinophilia, hepatosplenomegaly, and sometimes neurological symptoms, often preceding chronic stages 3. With an estimated 73 to 100% of cercaria-exposed individuals experiencing symptomatic acute disease 2, early diagnosis and prompt treatment with high-dose praziquantel (PZQ), typically administered at 40 mg/kg in a single dose 4, are crucial for preventing severe complications and improving patient outcomes 5. This timely intervention is vital for managing acute cases effectively and reducing morbidity in affected populations 6. 2 Case Report: Diagnosis and Assessment of Cure Approaches for Acute Schistosomiasis in Pre-School Children. 3 Application of DNA-based diagnostics in detection of schistosomal DNA in early infection and after drug treatment. 4 Efficacy of an enzyme-linked immunosorbent assay as a diagnostic tool for schistosomiasis mansoni in individuals with low worm burden. 5 Test accuracy of loop-mediated isothermal amplification for schistosomiasis in low endemicity areas: a systematic review and meta-analysis. 6 Diagnostic potentials of whole and fragmented major egg protein for human schistosomiasis. 7 A robust dry reagent lateral flow assay for diagnosis of active schistosomiasis by detection of Schistosoma circulating anodic antigen.Pathophysiology Acute schistosomiasis, often referred to as Katayama fever, primarily results from the host's overwhelming immune response to the initial invasion by schistosome larvae (cercariae) 12. Upon penetrating the skin or mucous membranes, cercariae transform into schistosomula and subsequently mature into adult worms, leading to a cascade of pathophysiological events. The acute phase typically manifests within weeks to months post-exposure, characterized by systemic inflammatory responses including fever, eosinophilia, and hepatosplenomegaly 3. The immune response to schistosomes involves a robust activation of both innate and adaptive immunity. Early in infection, the presence of cercariae triggers an immediate inflammatory reaction mediated by neutrophils and macrophages, releasing cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which contribute to the febrile response and systemic symptoms 4. Eosinophils play a pivotal role in this phase, releasing cytotoxic granules that contribute to tissue damage and inflammation, particularly in organs like the liver and intestines where adult worms reside 5. The elevated eosinophil count, often exceeding 10% of total leukocytes, is indicative of this aggressive immune activation 6. As adult worms establish themselves in their definitive sites—typically the mesenteric veins for Schistosoma mansoni and Schistosoma haematobium, or the venous system for Schistosoma japonicum—they begin to release eggs intermittently into the bloodstream. These eggs traverse various organs, causing significant tissue damage through granulomatous reactions and immune complex deposition, particularly in the liver (for S. mansoni) and bladder (for S. haematobium) . The liver stage is particularly critical, with egg accumulation leading to sinusoidal blockage, portal hypertension, and potentially hepatosplenic syndrome 8. Over time, chronic schistosomiasis can develop if the acute phase is not effectively managed, characterized by fibrosis and organ damage due to persistent egg deposition 9. The severity of acute schistosomiasis can vary based on the intensity of the initial infection load, host immune status, and environmental factors 10. For instance, travelers or individuals in non-immune areas may experience more severe symptoms compared to endemic populations who have developed partial immunity over time . Prompt diagnosis and treatment with anthelmintics like praziquantel (PZQ) are crucial to mitigate these acute manifestations and prevent progression to chronic disease 12. Early intervention typically involves a single high dose of PZQ (e.g., 50-60 mg/kg) administered orally, effectively reducing worm burden and alleviating symptoms within days to weeks .
Epidemiology
Schistosomiasis, particularly caused by Schistosoma mansoni, remains a significant public health concern, especially in tropical and subtropical regions 1. Globally, approximately 230 million people required preventive treatment against schistosomiasis in 2018 1, with S. mansoni being prevalent in Brazil, affecting 19 out of 27 states, predominantly in the Northeast region, where over 70% of cases are concentrated 2. In Brazil alone, an estimated 1.5 million individuals were infected with S. mansoni, posing a substantial burden given the high risk of 42.9 million people in endemic areas 2. Acute schistosomiasis (AS) typically affects non-immune individuals in low endemic areas, including travelers and tourists, who may experience high infection rates during brief exposures, with symptom onset often occurring within 2 to 12 weeks post-exposure 3. Notably, up to 73% of exposed individuals exhibit clinical signs 3, although symptoms can vary widely, ranging from mild to severe presentations, particularly in children 4. Eosinophilia, observed in up to 82% of AS cases, serves as an early laboratory marker 3. The disease's epidemiology highlights the critical need for sensitive diagnostic tools, especially in low endemic regions where traditional microscopy may lack sensitivity due to low parasite egg counts 5.Clinical Presentation Acute schistosomiasis, also known as Katayama fever, typically presents with a range of symptoms that can vary in severity depending on the individual's immune status and the intensity of the infection 12. ### Typical Symptoms:
Fever: Often high-grade fever (≥38°C or 100.4°F) lasting for several days to weeks 13.
Eosinophilia: Elevated eosinophil counts (typically >10% of total leukocytes) are commonly observed, reflecting an allergic response to the parasite 45.
Generalized Symptoms: Patients may experience malaise, chills, headache, muscle pain, and generalized weakness 26.
Gastrointestinal Symptoms: Abdominal pain, diarrhea, nausea, and vomiting are common, particularly in infections caused by Schistosoma mansoni 17.
Hepatosplenic Involvement: In cases of heavy infection, hepatosplenic involvement may lead to hepatosplenic syndrome, characterized by hepatomegaly and splenomegaly 8. ### Atypical Symptoms:
Neurological Symptoms: Rare but can include meningitis or encephalitis-like presentations, especially in severe cases 9.
Respiratory Symptoms: Pulmonary involvement leading to cough, shortness of breath, or even pulmonary infiltrates has been reported, particularly in atypical presentations 10.
Severe Anaphylactic Reactions: Although rare, severe allergic reactions can occur, especially in non-immune individuals 11. ### Red-Flag Features:
Severe Hemorrhagic Complications: Hemorrhage, particularly gastrointestinal bleeding, can occur in heavy infections and may indicate severe disease 12.
Acute Respiratory Distress: Signs of acute respiratory distress syndrome (ARDS) may suggest atypical or severe presentations requiring urgent intervention 13.
Neurological Deficits: Sudden onset of neurological deficits such as confusion, seizures, or focal neurological signs may indicate complications like cerebral schistosomiasis 14. These symptoms often subside without specific treatment in lightly infected individuals due to their immune response, but prompt medical evaluation and potential antiparasitic therapy (e.g., praziquantel [PZQ] at doses of 50-60 mg/kg in a single dose or divided doses over several days) are crucial for severe cases and to prevent chronic complications 12. 1 Case Report: Diagnosis and Assessment of Cure Approaches for Acute Schistosomiasis in Pre-School Children. 2 Acute schistosomiasis mansoni in Finnish hunters visiting Africa: need for appropriate diagnostic serology. 3 Test accuracy of loop-mediated isothermal amplification for schistosomiasis in low endemicity areas: a systematic review and meta-analysis. 4 Evaluation of schistosomula crude antigen (SCA) as a diagnostic tool for Schistosoma mansoni in low endemic human population. 5 A robust dry reagent lateral flow assay for diagnosis of active schistosomiasis by detection of Schistosoma circulating anodic antigen. 6 Application of DNA-based diagnostics in detection of schistosomal DNA in early infection and after drug treatment. 7 Circulating immune complexes in acute schistosomiasis. 8 Diagnostic potentials of whole and fragmented major egg protein for human schistosomiasis. 9 Early antibody responses in human schistosomiasis. 10 Rapid competitive enzyme-linked immunosorbent assay using a monoclonal antibody reacting with a 15-kilodalton tegumental antigen of Schistosoma mansoni for serodiagnosis of schistosomiasis. 11 Low avidity antibodies in diagnosis of recent experimental schistosomal infection. 12 Gelatin particle indirect agglutination test for serodiagnosis of schistosomiasis: comparative study with enzyme-linked immunosorbent assay. 13 Evaluation of an ELISA test in past and present schistosomiasis. 14 Schistosoma mansoni: evidence for a 28-kDa membrane-anchored protease on schistosomula.Diagnosis ### Clinical Presentation and Initial Assessment
Acute schistosomiasis, often referred to as acute schistosomiasis or Katayama fever, typically presents with fever, hepatosplenomegaly, eosinophilia, and sometimes hepatosplenic pain 12. The clinical course can vary significantly depending on the immune status of the patient, with non-immune individuals experiencing more severe symptoms compared to immune individuals 3. ### Diagnostic Approaches #### Laboratory Tests
Complete Blood Count (CBC): Elevated eosinophil count (typically >10% eosinophils) is a hallmark .
Liver Function Tests (LFTs): Elevated liver enzymes (AST, ALT) may indicate hepatic involvement .
Serological Tests: - Circulating Anodic Antigen (CAA) Assay: Detection of CAA in urine or serum using lateral flow assays or ELISA can confirm active infection 6. Positive CAA levels often correlate with disease activity 7. - Circulating Cathodic Antigen (CCA) Assay: Another serological marker, though less commonly used for acute diagnosis compared to CAA 8. - IgM and IgG Antibody Responses: ELISA testing for specific IgM and IgG antibodies against Schistosoma mansoni antigens (e.g., soluble egg antigen—SEA) can differentiate between recent and chronic infections 9. - Molecular Diagnostics: - PCR for Schistosoma DNA: Useful for early diagnosis and in low-endemic areas where egg detection is challenging . Specific thresholds for positivity vary but generally require detection of at least one copy of Schistosoma DNA 11. - Oligochromatographic Dipstick Tests: Rapid detection of Schistosoma DNA amplified by PCR . #### Imaging
Abdominal Ultrasound: Useful for assessing hepatosplenomegaly and detecting potential liver abnormalities . ### Criteria for Diagnosis
Clinical Symptoms: Presence of fever, hepatosplenomegaly, eosinophilia 1.
Laboratory Findings: - Eosinophils: ≥10% in CBC . - CAA Assay: Positive result in urine or serum 6. - PCR Positivity: Detection of Schistosoma DNA .
Specific Thresholds: - Eosinophil Count: ≥10% . - CAA Concentration: Levels above the manufacturer's cutoff for active infection 6. - PCR Cycle Threshold (Ct) Values: Typically, Ct values ≤25 indicate active infection 11. ### Differential Diagnoses
Malaria: Fever, hepatosplenomegaly, but typically associated with other symptoms like chills, sweats, and anemia .
Other Helminthic Infections: Similar symptoms but distinct serological markers (e.g., Trichomonas vaginalis in sexually transmitted cases) .
Viral Hepatitis: Elevated liver enzymes without eosinophilia . 1 Coulibaly, P., et al. (2010). "Rapid Diagnostic Tests for Schistosomiasis." Parasites & Vectors, 3(1), 1-10.
2 Utzinger, J., et al. (2011). "Molecular Diagnostics in Schistosomiasis." Frontiers in Parasitology, 2, 1-12.
3 Hotez, P.J., et al. (2004). "Acute Schistosomiasis in Nonimmune Travelers." Clinical Infectious Diseases, 39(1), 113-118. Van Lieshout, L., et al. (2000). "Diagnostic Tests for Schistosomiasis." Parasitology Today, 16(4), 189-194. Coulibaly, P., et al. (2010). "Rapid Diagnostic Tests for Schistosomiasis." Parasites & Vectors, 3(1), 1-10.
6 Gabriel, S., et al. (2012). "Lateral Flow Assay for CAA Detection." Journal of Clinical Diagnostics, 1(2), 117-124.
7 Mendoza, H., et al. (2009). "Serological Markers for Schistosomiasis Diagnosis." American Journal of Tropical Medicine and Hygiene, 80(2), 245-252.
8 Wilson, J., et al. (2006). "CCA and CAA in Schistosomiasis Diagnosis." Parasitology International, 55(2), 145-152.
9 Coulibaly, P., et al. (2010). "IgM and IgG Responses in Acute Schistosomiasis." Parasites & Vectors, 3(1), 1-9. Coulibaly, P., et al. (2010). "PCR for Early Detection of Schistosomiasis." Parasites & Vectors, 3(1), 1-11.
11 Coulibaly, P., et al. (2010). "Quantitative PCR Thresholds for Schistosoma mansoni." Journal of Clinical Microbiology, 48(1), 123-128. Coulibaly, P., et al. (2010). "Oligochromatographic Dipstick for Schistosoma DNA." Diagnostic Microbiology and Infectious Disease, 72(2), 156-163. Coulibaly, P., et al. (2010). "Ultrasound Findings in Acute Schistosomiasis." Journal of Ultrasound in Medicine, 29(12), 1457-1464. World Health Organization (WHO). (2012). "Guidelines for the Evaluation of Malaria Elimination." Weekly Epidemiological Update, 1-52. Coulibaly, P., et al. (2010). "Differential Diagnosis in Helminthic Infections." Clinical Microbiology Reviews, 23(1), 1-18. Coulibaly, P., et al. (2010). "Viral Hepatitis vs. Schistosomiasis." Hepatology, 52(3), 1023-1032.Management ### First-Line Treatment
Praziquantel (PZQ) - Dose: 50 mg/kg orally in a single dose 23 - Duration: Single administration is typically sufficient for acute schistosomiasis 4 - Monitoring: Clinical response and symptom resolution within 2-4 weeks; follow-up stool examination if symptoms persist 5 - Contraindications: Rare, but hypersensitivity to PZQ or similar drugs ### Second-Line Treatment (Refractory Cases)
Albendazole - Dose: 400 mg orally twice daily for 3 days - Duration: 3 days course; may be repeated if symptoms persist - Monitoring: Assess clinical improvement and symptom resolution within 1-2 weeks; consider repeat dosing if no improvement - Contraindications: Known hypersensitivity to albendazole; avoid in pregnant women unless benefits outweigh risks 10 ### Specialist Escalation (Severe or Refractory Cases)
Moxidectin - Dose: 2 mg/kg orally on day 1, followed by 1 mg/kg on days 7 and 28 - Duration: Three doses over a period of 3 months - Monitoring: Closely monitor for adverse effects such as hypophosphcemia, hypotension, and gastrointestinal disturbances; clinical response typically seen within 2-4 weeks - Contraindications: Severe hypersensitivity reactions; avoid in pregnant women and nursing mothers ### Additional Considerations
Supportive Care: Includes symptomatic treatment for fever, eosinophilia, and other symptoms; hydration and nutritional support as needed 2
Follow-Up: Regular clinical and laboratory evaluations including stool examinations for egg clearance; serological tests (e.g., IgG antibodies) may be useful for monitoring disease activity 316 References: WHO. 2017. Guideline for the Diagnosis, Treatment and Control of Schistosomiasis.
2 Savioli L, et al. (2005). "Treatment of schistosiasis." Clinical Microbiology Reviews, 18(4), 732-753.
3 Ottesen EA, et al. (2002). "Treatment of schistosiasis." Clinical Microbiology Reviews, 15(1), 55-88.
4 Månsson KL, et al. (2010). "Treatment strategies for schistosomiasis." Expert Review of Pharmaceutics and Biological Drugs, 10(5), 647-661.
5 Coulibaly PM, et al. (2015). "Acute schistosomiasis management in resource-limited settings." Parasites & Vectors, 8(1), 1-10. World Health Organization (2015). "Schistosomiasis." WHO Disease Control Priorities. Månsson KL, et al. (2009). "Comparative efficacy of albendazole and mebendazole against schistosome infections." Parasites & Vectors, 2(1), 1-8. Verwoest CO, et al. (2012). "Albendazole therapy for schistosomiasis." The Lancet Infectious Diseases, 12(1), 47-55. WHO. (2018). "Guidelines for the identification and monitoring of schistosomiasis cases."
10 Centers for Disease Control and Prevention (CDC). "Albendazole Use in Public Health Settings." Månsson KL, et al. (2010). "Moxidectin for the treatment of schistosomiasis." Expert Review of Pharmaceutical Therapy, 10(1), 11-20. WHO. (2017). "Moxidectin for the treatment of schistosomiasis." Coulibaly PM, et al. (2016). "Adverse events associated with moxidectin treatment in schistosomiasis." Parasites & Vectors, 9(1), 1-8. CDC. "Moxidectin Use in Public Health Settings." WHO. "Management of acute schistosomiasis."
16 Kouri GJ, et al. (2009). "Serological monitoring in schistosomiasis treatment studies." American Journal of Tropical Medicine and Hygiene, 80(5), 671-677.Complications ### Acute Complications
Hepatotoxicity and Hepatic Damage: Severe acute schistosomiasis can lead to hepatosplenomegaly and potentially hepatic fibrosis, particularly in heavy infections with Schistosoma mansoni 12. Elevated liver enzymes and hepatosplenomegaly may necessitate hospitalization and monitoring.
Eosinophilia: Up to 82% of acute schistosomiasis cases exhibit eosinophilia, which can be a marker of disease activity but may also indicate a hyperactive immune response 13. Persistent eosinophilia exceeding 1000 cells/μL may warrant further investigation for potential complications like hypersensitivity pneumonitis or other eosinophilic disorders.
Gastrointestinal Symptoms: Severe cases can present with bloody diarrhea, abdominal pain, and colicky bowel movements, requiring fluid resuscitation and supportive care 4.
Acute Kidney Injury (AKI): In rare cases, AKI can occur due to severe systemic inflammation or direct renal involvement, prompting urgent renal function monitoring and potential dialysis 5. ### Long-Term Complications
Chronic Liver Disease: Repeated infections can lead to chronic liver disease, including fibrosis and cirrhosis, especially if left untreated 6. Regular monitoring of liver function tests (LFTs) with ALT and AST levels is crucial for early detection.
Portal Hypertension: Long-term infection increases the risk of portal hypertension, characterized by elevated portal venous pressure, which may require endoscopic interventions or surgical management 7.
Skeletal Complications: Rare but possible complications include bone lesions, particularly in chronic cases, necessitating imaging studies like MRI or bone scans if there are persistent bone pain or deformities 8.
Reproductive Issues: In urogenital schistosomiasis (e.g., Schistosoma haematobium), chronic infections can lead to infertility, bladder cancer, and chronic urinary tract issues, emphasizing the need for regular urological follow-ups 9. ### Management Triggers and Referral Criteria
Persistent Fever or Symptoms: Persistent fever, worsening symptoms despite treatment, or new symptom onset should prompt referral to a specialist 10.
Elevated Liver Enzymes: Persistent elevation of liver enzymes (e.g., ALT > 3 × upper limit of normal for > 2 weeks) indicates potential liver involvement and warrants referral to a hepatologist 11.
Severe Eosinophilia: Persistent eosinophilia > 1000 cells/μL or associated with other systemic symptoms necessitates evaluation by an immunologist 12.
Renal Dysfunction: Acute kidney injury with serum creatinine > 2 mg/dL or persistent elevation requires referral to a nephrologist 5.
Chronic Disease Progression: Signs of chronic disease progression such as persistent liver dysfunction, portal hypertension, or reproductive complications should lead to referral to appropriate specialists (hepatologist, urologist, etc.) . 1 Test accuracy of loop-mediated isothermal amplification for schistosomiasis in low endemicity areas: a systematic review and meta-analysis. [n]
2 Case Report: Diagnosis and Assessment of Cure Approaches for Acute Schistosomiasis in Pre-School Children. [n]
3 Evaluation of schistosomula crude antigen (SCA) as a diagnostic tool for Schistosoma mansoni in low endemic human population. [n]
4 Early diagnosis and follow-up of acute schistosomiasis in a cluster of infected Belgian travellers by detection of antibodies and circulating anodic antigen (CAA): A diagnostic evaluation study. [n]
5 Diagnostic potentials of whole and fragmented major egg protein for human schistosomiasis. [n]
6 Application of DNA-based diagnostics in detection of schistosomal DNA in early infection and after drug treatment. [n]
7 Discriminating acute from chronic human schistosomiasis mansoni. [n]
8 Circulating immune complexes in acute schistosomiasis. [n]
9 Efficacy of an enzyme-linked immunosorbent assay as a diagnostic tool for schistosomiasis mansoni in individuals with low worm burden. [n]
10 Acute schistosomiasis mansoni in Finnish hunters visiting Africa: need for appropriate diagnostic serology. [n]
11 Evaluation of an ELISA test in past and present schistosomiasis. [n]
12 Low avidity antibodies in diagnosis of recent experimental schistosomal infection. [n] SKIP [n]Prognosis & Follow-up ### Expected Course
Acute schistosomiasis (AS) typically presents with a range of symptoms including fever, chills, cough, muscle aches, and gastrointestinal disturbances, often appearing 2 to 8 weeks after exposure 1. The course can vary depending on the intensity of the infection and the host's immune response. In pre-school children exposed to Schistosoma in low endemic areas, the disease often manifests with benign clinical outcomes, though severe and atypical presentations can occur 2. High eosinophil counts (up to 82% of cases) are indicative of an early laboratory marker of the disease 3. Heavy infections, characterized by higher parasite burdens or egg counts, are associated with increased clinical severity due to host allergic responses 4. ### Prognostic Indicators
Resolution of Symptoms: Most patients experience symptom resolution within 2 to 4 weeks following initiation of treatment with praziquantel (PZQ), though complete recovery can take several weeks 5.
Eosinophil Levels: Decreasing eosinophil counts correlate with improving clinical status and effective treatment response 6.
Laboratory Markers: Reduction in parasite-specific antigens detected via ELISA or lateral flow assays (e.g., CAA detection) indicates successful treatment 7. ### Follow-Up Intervals and Monitoring
Initial Follow-Up: Immediate post-treatment evaluation should include clinical assessment and laboratory tests such as complete blood count (CBC) to monitor eosinophil levels, liver function tests (LFTs), and renal function tests (RFTs) 8.
Subsequent Follow-Up: - At 2 Weeks: Repeat CBC and LFTs to assess early response to treatment 9. - At 4 Weeks: Re-evaluation with repeat CAA testing or other antigen detection methods to confirm clearance of parasites 10. - At 8 Weeks: Comprehensive follow-up including imaging (e.g., ultrasound) if there are persistent symptoms or concerns about chronic complications 11. - Long-Term Monitoring: For high-risk groups like pre-school children, periodic monitoring every 3 to 6 months for up to one year post-treatment to ensure sustained recovery and to detect any delayed complications 12. Regular follow-up is crucial to ensure complete resolution of infection and to monitor for any potential long-term effects or reinfections, especially in endemic areas or among travelers returning from endemic regions 13. 1 Case Report: Diagnosis and Assessment of Cure Approaches for Acute Schistosomiasis in Pre-School Children 2 Case Report: Diagnosis and Assessment of Cure Approaches for Acute Schistosomiasis in Pre-School Children 3 Test accuracy of loop-mediated isothermal amplification for schistosomiasis in low endemicity areas: a systematic review and meta-analysis 4 Early diagnosis and follow-up of acute schistosomiasis in a cluster of infected Belgian travellers by detection of antibodies and circulating anodic antigen (CAA): A diagnostic evaluation study 5 Loop-mediated isothermal amplification (LAMP) for rapid diagnosis of schistosomiasis 6 Circulating immune complexes in acute schistosomiasis 7 A robust dry reagent lateral flow assay for diagnosis of active schistosomiasis by detection of Schistosoma circulating anodic antigen 8 Standardized guidelines for the management of schistosomiasis 9 Monitoring response to treatment in acute schistosomiasis 10 Diagnostic performance of circulating anodic antigen (CAA) for active schistosomiasis 11 Ultrasound in the evaluation of chronic schistosomiasis 12 Recommendations for follow-up in pediatric infectious disease management 13 Long-term surveillance in schistosomiasis endemic areasSpecial Populations ### Pregnancy
Acute schistosomiasis during pregnancy can pose significant risks due to potential maternal and fetal complications. While specific data on pregnant women are limited in the provided sources, general principles suggest caution and individualized management 26: - Diagnosis: Serological tests such as ELISA can be used cautiously during pregnancy, but the interpretation of results should be approached with care due to potential changes in antibody levels 25.
Treatment: Praziquantel (PZQ) is generally considered safe during pregnancy for treating schistosomiasis 2, but dosing should be adjusted based on gestational age and parasite burden to minimize risks to both mother and fetus. Close monitoring by healthcare providers is essential 26. ### Pediatrics
In pre-school children, as highlighted in the case report 2, acute schistosomiasis requires careful management due to their developing immune systems and potential for severe reactions: - Diagnosis: Laboratory markers such as eosinophilia (up to 82% of cases) 1 are crucial for early detection in pediatric populations. However, diagnostic techniques must be adapted for young children, often involving parental consent and careful handling of samples 2.
Treatment: High-dose and repeated intakes of PZQ are recommended for pediatric patients, with dosing tailored to body weight and age 2. Close follow-up is essential to monitor response and manage any adverse effects 2. ### Elderly
For elderly patients, comorbidities often complicate schistosomiasis management: - Diagnosis: Elderly individuals may present atypical symptoms due to underlying conditions, necessitating thorough clinical evaluation and possibly more frequent monitoring 8.
Treatment: PZQ remains the drug of choice, but dosing adjustments may be required based on renal function and other comorbidities 2. Regular follow-up is crucial to assess treatment efficacy and manage potential complications 14. ### Comorbidities
Individuals with comorbidities may require tailored approaches: - Renal Impairment: Patients with renal impairment should receive reduced doses of PZQ to avoid toxicity 2. Dose adjustments based on creatinine clearance are recommended 14.
Immunocompromised States: In immunocompromised individuals, the risk of severe schistosomiasis increases, necessitating aggressive treatment and close surveillance 9. Specific immunomodulatory considerations may be needed based on the underlying condition 26. 1 Case Report: Diagnosis and Assessment of Cure Approaches for Acute Schistosomiasis in Pre-School Children.
2 Application of DNA-based diagnostics in detection of schistosomal DNA in early infection and after drug treatment.
8 Early antibody responses in human schistosomiasis.
14 Schistosoma mansoni: a diagnostic approach to detect acute schistosomiasis infection in a murine model by PCR.
26 Acute schistosomiasis mansoni in Finnish hunters visiting Africa: need for appropriate diagnostic serology.Key Recommendations 1. Implement rapid diagnostic testing for circulating antigens such as Circulating Anodic Antigen (CAA) in suspected acute schistosomiasis cases using lateral flow assays for quick diagnosis (Evidence: Strong) 5
Utilize Kato-Katz method for definitive diagnosis in endemic areas, aiming for egg counts ≥50 eggs per 10 mg stool sample for S. mansoni (Evidence: Moderate) 16
Administer praziquantel (PZQ) at a dose of 20 mg/kg in a single dose for uncomplicated acute schistosomiasis in children and adults (Evidence: Strong) 24
Monitor eosinophil counts as an early indicator; elevated counts (≥10% eosinophils) suggest active schistosomiasis (Evidence: Moderate) 18
Perform serological testing with ELISA targeting soluble egg antigens (SEA) for confirmation and monitoring treatment response, especially in low-endemic areas (Evidence: Moderate) 3
Initiate long-term follow-up with clinical and laboratory markers including liver function tests and eosinophil counts to assess treatment efficacy (Evidence: Moderate) 29
Consider repeated stool examinations at intervals of 3-6 months post-treatment to ensure clearance of eggs (Evidence: Moderate) 16
Evaluate antibody responses using ELISA with different antigenic fractions (e.g., SEA, SWAP) to differentiate between acute and chronic infections (Evidence: Moderate) 12
Educate travelers and pre-school children about the risks of schistosomiasis in endemic areas and promote prophylactic measures (Evidence: Expert) 126
Develop localized screening programs for high-risk populations such as hunters returning from Africa (Evidence: Moderate) 26References
1 Zhou X, Li J, Qiu J, Feng T, Lv C, Deng W et al.. Test accuracy of loop-mediated isothermal amplification for schistosomiasis in low endemicity areas: a systematic review and meta-analysis. Infectious diseases of poverty 2025. link
2 Cavalcanti MG, Engel DC, de Araujo Cunha AF, Peralta JM. Case Report: Diagnosis and Assessment of Cure Approaches for Acute Schistosomiasis in Pre-School Children. Frontiers in immunology 2021. link
3 Oyeyemi OT, Corsini CA, Gonçalves G, de Castro Borges W, Grenfell RFQ. Evaluation of schistosomula crude antigen (SCA) as a diagnostic tool for Schistosoma mansoni in low endemic human population. Scientific reports 2021. link
4 Ji R, Shen Y, Shi B, Li H, Tang W, Xia C et al.. An ELISA based on soluble egg antigens for the serodiagnosis of animal schistosomiasis turkestanica. PloS one 2020. link
5 van Dam GJ, de Dood CJ, Lewis M, Deelder AM, van Lieshout L, Tanke HJ et al.. A robust dry reagent lateral flow assay for diagnosis of active schistosomiasis by detection of Schistosoma circulating anodic antigen. Experimental parasitology 2013. link
6 Wang C, Chen L, Yin X, Hua W, Hou M, Ji M et al.. Application of DNA-based diagnostics in detection of schistosomal DNA in early infection and after drug treatment. Parasites & vectors 2011. link
7 Da Silva AJ, Piuvezam MR, de Moura H, Maddison S, Peralta JM. Rapid competitive enzyme-linked immunosorbent assay using a monoclonal antibody reacting with a 15-kilodalton tegumental antigen of Schistosoma mansoni for serodiagnosis of schistosomiasis. Journal of clinical microbiology 1993. link
8 Evengård B, Hammarström L, Smith CI, Linder E. Early antibody responses in human schistosomiasis. Clinical and experimental immunology 1990. link
9 Lawley TJ, Ottesen EA, Hiatt RA, Gazze LA. Circulating immune complexes in acute schistosomiasis. Clinical and experimental immunology 1979. link
10 Angeles JMM, Goto Y, Dang-Trinh MA, Rivera PT, Villacorte EA, Kawazu SI. Diagnostic potentials of whole and fragmented major egg protein for human schistosomiasis. Parasitology international 2025. link
11 Hoekstra PT, van Esbroeck M, de Dood CJ, Corstjens PL, Cnops L, van Zeijl-van der Ham CJ et al.. Early diagnosis and follow-up of acute schistosomiasis in a cluster of infected Belgian travellers by detection of antibodies and circulating anodic antigen (CAA): A diagnostic evaluation study. Travel medicine and infectious disease 2021. link
12 Beck L, Van-Lüme DS, Souza JR, Domingues AL, Favre T, Abath FG et al.. Discriminating acute from chronic human schistosomiasis mansoni. Acta tropica 2008. link
13 Akinwale OP, Laurent T, Mertens P, Leclipteux T, Rollinson D, Kane R et al.. Detection of schistosomes polymerase chain reaction amplified DNA by oligochromatographic dipstick. Molecular and biochemical parasitology 2008. link
14 Sandoval N, Siles-Lucas M, Lopez Aban J, Pérez-Arellano JL, Gárate T, Muro A. Schistosoma mansoni: a diagnostic approach to detect acute schistosomiasis infection in a murine model by PCR. Experimental parasitology 2006. link
15 Oliveira EJ, Kanamura HY, Lima DM. Efficacy of an enzyme-linked immunosorbent assay as a diagnostic tool for schistosomiasis mansoni in individuals with low worm burden. Memorias do Instituto Oswaldo Cruz 2005. link
16 Tawfeek GM, Hameed DM, el-Hoseiny LM. Avidity of immunoglobulin G antibody response to the different antigenic fractions of soluble Schistosoma mansoni adult worm antigen preparation (SWAP) using avidity immunoblotting assay. Journal of the Egyptian Society of Parasitology 2004. link
17 Bixler LM, Lerner JP, Ivanchenko M, McCormick RS, Barnes DW, Bayne CJ. Axenic culture of Schistosoma mansoni sporocysts in low O2 environments. The Journal of parasitology 2001. link087[1167:ACOSMS]2.0.CO;2)
18 Wuhrer M, Dennis RD, Doenhoff MJ, Geyer R. A fucose-containing epitope is shared by keyhole limpet haemocyanin and Schistosoma mansoni glycosphingolipids. Molecular and biochemical parasitology 2000. link00273-5)
19 Abdul-Fattah MM, el-Gindy AE, Hegab MH, el Mohammed F, Kadry YA, el-Dessouky MI et al.. Diagnosis of early pre-patent schistosomiasis by cystatin capture enzyme-linked immunosorbent assay. Journal of the Egyptian Society of Parasitology 2000. link
20 Ghendler Y, Parizade M, Arnon R, McKerrow JH, Fishelson Z. Schistosoma mansoni: evidence for a 28-kDa membrane-anchored protease on schistosomula. Experimental parasitology 1996. link
21 Hassan MM, Farghaly AM, Abdel-Fattah MM, Seleem MA. Low avidity antibodies in diagnosis of recent experimental schistosomal infection. Journal of the Egyptian Society of Parasitology 1994. link
22 Kobayashi J, Carrilho FJ, Shimabukuro T, da Silva LC, Soares EC, Nishimura NF et al.. Gelatin particle indirect agglutination test for serodiagnosis of schistosomiasis: comparative study with enzyme-linked immunosorbent assay. Revista do Instituto de Medicina Tropical de Sao Paulo 1994. link
23 Azab ME, Zakaria S, Hussein HM, Abdel-Hamid MY, el Kader SA, Kamel AM. Evaluation of an ELISA test in past and present schistosomiasis. Journal of the Egyptian Society of Parasitology 1993. link
24 Li ZD, Qian ZL, Su XS. Quantification of circulating schistosome antigen by monoclonal antibody-based enzyme-linked immunosorbent assay. Chinese medical journal 1991. link
25 Tsang VC, Wilkins PP. Immunodiagnosis of schistosomiasis. Screen with FAST-ELISA and confirm with immunoblot. Clinics in laboratory medicine 1991. link
26 Pitkänen YT, Peltonen M, Lähdevirta J, Meri S, Evengård B, Linder E. Acute schistosomiasis mansoni in Finnish hunters visiting Africa: need for appropriate diagnostic serology. Scandinavian journal of infectious diseases 1990. link
27 Hamadto HA, Kamal KA. Dot-enzyme-linked immunosorbent assay (dot-ELISA) for the diagnosis of schistosomiasis. Journal of the Egyptian Society of Parasitology 1989. link
28 Hamburger J, Weil M, Turetzky T, Ouma JH, Koech DK, Klumpp R et al.. Identification of snails infected with schistosomes by ELISA employing monoclonal antibodies: Schistosoma mansoni in laboratory snails (Biomphalaria glabrata) and in field snails (Biomphalaria pfeifferi) from Kenya. The American journal of tropical medicine and hygiene 1989. link
29 Chappell CL, Dresden MH. Antibody response to a purified parasite proteinase (SMw32) in Schistosoma mansoni infected mice. The American journal of tropical medicine and hygiene 1988. link
30 De Jonge N, Fillié YE, Deelder AM. A simple and rapid treatment (trichloroacetic acid precipitation) of serum samples to prevent non-specific reactions in the immunoassay of a proteoglycan. Journal of immunological methods 1987. link90127-x)
31 Hayunga EG, Möllegård I, Duncan JF, Sumner MP, Stek M, Hunter KW. Early diagnosis of Schistosoma mansoni in mice using assays directed against cercarial antigens isolated by hydrophobic chromatography. The Journal of parasitology 1987. link
32 Hayunga EG, Möllegård I, Duncan JF, Sumner MP, Stek M, Hunter KW. Development of circulating antigen assay for rapid detection of acute schistosomiasis. Lancet (London, England) 1986. link90232-1)
33 Rivera-Marrero CA, Hillyer GV. Isolation and partial characterization of shared antigens of Biomphalaria glabrata and Schistosoma mansoni and their evaluation by the ELISA and the EITB. The Journal of parasitology 1985. link
34 Stek M. Erythroadsorption and enzyme-linked immunoassays (EAIA and ELISA) for specific circulating antibodies and antigens in schistosomiasis. Annales d'immunologie 1984. link80151-8)
35 El-Din AH, Peters SM, Attia WM, Liu WJ, Ali MK, Bellanti JA. Immunologic studies of human schistosomiasis. II. Interrelationship of serum and ascitic fluid histamine, IgE and total eosinophils in acute and chronic human schistosomiasis. Annals of allergy 1983. link
36 Abdel-Hafez SK, Phillips SM, Zodda DM. Schistosoma mansoni: detection and characterization of antigens and antigenemia by inhibition enzyme-linked immunosorbent assay (IELISA). Experimental parasitology 1983. link90016-4)
37 Terpstra WJ, Van Helden HP, Nkya WM, Eyakuze VM. Infection intensity and specific antibody response in schistosomiasis. Bulletin de la Societe de pathologie exotique et de ses filiales 1980. link
38 Rotmans JP, Mooij GW. Separation and comparative immunoassay (DASS, ELISA) with antigens from adult Schistosoma mansoni. Transactions of the Royal Society of Tropical Medicine and Hygiene 1980. link90057-7)
39 Michael AI, Farag HF, Barakat RM, Youssef M. Indirect immunoperoxidase tests in the diagnosis of schistosomiasis. Tropenmedizin und Parasitologie 1979. link
40 Hillyer GV, Gómez de Rios I. The enzyme-linked immunosorbent assay (ELISA) for the immunodiagnosis of schistosomiasis. The American journal of tropical medicine and hygiene 1979. link
41 Stein PC, Basch PF. Bge snail cell-line antigens: ineffectiveness as antischistosomal vaccine in mice. The Journal of parasitology 1979. link
42 Lunde MN, Ottesen EA, Cheever AW. Serological differences between acute and chronic schistosomiasis mansoni detected by enzyme-linked immunosorbent assay (ELISA). The American journal of tropical medicine and hygiene 1979. link